FranÃ§ois Lang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2759871/publications.pdf

Version: 2024-02-01

46 papers	1,272 citations	394421 19 h-index	361022 35 g-index
46 all docs	46 docs citations	46 times ranked	1756 citing authors

#	Article	IF	Citations
1	hnRNPâ€A1 binds to the IRES of MELOEâ€1 antigen to promote MELOEâ€1 translation in stressed melanoma cells. Molecular Oncology, 2022, 16, 594-606.	4.6	9
2	Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2021, 70, 3015-3030.	4.2	6
3	Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells. OncoImmunology, 2019, 8, e1560919.	4.6	29
4	TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features. Frontiers in Immunology, 2018, 9, 1962.	4.8	12
5	Emergence of High-Avidity Melan-Aâ€“Specific Clonotypes as a Reflection of Antiâ€“PD-1 Clinical Efficacy. Cancer Research, 2017, 77, 7083-7093.	0.9	20
6	PD-1 expression conditions T cell avidity within an antigen-specific repertoire. OncoImmunology, 2016, 5, e1104448.	4.6	47
7	IRES-dependent translation of the long non coding RNA meloe in melanoma cells produces the most immunogenic MELOE antigens. Oncotarget, 2016, 7, 59704-59713.	1.8	40
8	Soluble HLA-I/Peptide Monomers Mediate Antigen-Specific CD8 T Cell Activation through Passive Peptide Exchange with Cell-Bound HLA-I Molecules. Journal of Immunology, 2014, 192, 5090-5097.	0.8	13
9	The Melanoma Antigens MELOE-1 and MELOE-2 Are Translated from a Bona Fide Polycistronic mRNA Containing Functional IRES Sequences. PLoS ONE, 2013, 8, e75233.	2.5	25
10	Overexpression of Meloe Gene in Melanomas Is Controlled Both by Specific Transcription Factors and Hypomethylation. PLoS ONE, 2013, 8, e75421.	2.5	10
11	A Full GMP Process to Select and Amplify Epitope-Specific T Lymphocytes for Adoptive Immunotherapy of Metastatic Melanoma. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	20
12	CD137 on inflamed lymphatic endothelial cells enhances CCL21â€guided migration of dendritic cells. FASEB Journal, 2012, 26, 3380-3392.	0.5	45
13	MELOE-1 Antigen Contains Multiple HLA Class II T Cell Epitopes Recognized by Th1 CD4+ T Cells from Melanoma Patients. PLoS ONE, 2012, 7, e51716.	2.5	10
14	A simple competitive assay to determine peptide affinity for HLA class II molecules: A useful tool for epitope prediction. Journal of Immunological Methods, 2011, 371, 97-105.	1.4	14
15	A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination. Cancer Immunology, Immunotherapy, 2011, 60, 327-337.	4.2	15
16	Is antigen specificity the key to efficient adoptive T-cell therapy?. Immunotherapy, 2011, 3, 495-505.	2.0	4
17	Synthesis of N-Pyridinyl(methyl)-1,2-dihydro-4-hydroxy-2-oxoquinoline-3-carboxamides and analogues and their anti-inflammatory activity in mice and rats. Journal of Pharmacy and Pharmacology, 2010, 53, 417-423.	2.4	19
18	An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context. Cancer Immunology, Immunotherapy, 2010, 59, 431-439.	4.2	14

#	Article	IF	Citations
19	Synthesis of N-aryl-3-(indol-3-yl)propanamides and their immunosuppressive activities. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5203-5206.	2.2	5
20	The Angiogenic Growth Factor and Biomarker Midkine Is a Tumor-Shared Antigen. Journal of Immunology, 2010, 185, 418-423.	0.8	30
21	A Novel Indole-3-propanamide Exerts Its Immunosuppressive Activity by Inhibiting JAK3 in T Cells. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 710-716.	2.5	8
22	A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunology, Immunotherapy, 2009, 58, 553-566.	4.2	23
23	CD137 Is Expressed in Human Atherosclerosis and Promotes Development of Plaque Inflammation in Hypercholesterolemic Mice. Circulation, 2008, 117, 1292-1301.	1.6	188
24	Synthetic N-pyridinyl(methyl)-indol-3-ylpropanamides as new potential immunosuppressive agents. European Journal of Medicinal Chemistry, 2007, 42, 686-693.	5.5	7
25	PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunology, Immunotherapy, 2007, 57, 185-195.	4.2	19
26	A new carboxamide compound exerts immuno-suppressive activity by inhibiting dendritic cell maturation. European Journal of Immunology, 2005, 35, 546-556.	2.9	22
27	Production of Recombinant Human Trimeric CD137L (4-1BBL). Journal of Biological Chemistry, 2005, 280, 41472-41481.	3.4	50
28	Adoptive Transfer of Tumor-Reactive Melan-A-Specific CTL Clones in Melanoma Patients Is Followed by Increased Frequencies of Additional Melan-A-Specific T Cells. Journal of Immunology, 2005, 175, 4797-4805.	0.8	93
29	Synthesis and Evaluation of Disubstituted N1- and N3-Imidazolidin-2-ones Acting as Potential Immunosuppressive Agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 459-465.	5.2	5
30	Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells. Blood, 2003, 102, 1241-1248.	1.4	21
31	Retrovirus-mediated gene transfer in primary T lymphocytes impairs their antiâ€“Epstein-Barr virus potential through both culture-dependent and selection processâ€“dependent mechanisms. Blood, 2002, 99, 1165-1173.	1.4	109
32	Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. International Journal of Cancer, 2002, 101, 280-286.	5.1	36
33	CD8: from coreceptor to comodulator. Nature Immunology, 2002, 3, 12-14.	14.5	14
34	MHC-peptide multimers:tools of choice for detecting and sorting antigen-specific T-cells. Transfusion, 2001, 41, 687-690.	1.6	0
35	Frequent recognition of BCRF1, a late lytic cycle protein of Epstein-Barr virus, in the HLA-B*2705 context: evidence for a TAP-independent processing. European Journal of Immunology, 2001, 31, 708-715.	2.9	19
36	Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nature Medicine, 2000, 6, 707-710.	30.7	146

#	Article	IF	Citations
37	Non-carboxylic antiinflammatory compounds. III. N-(4,6-Dimethylpyridin-2-yl)arylcarboxamides and arylthiocarboxamides acting as brain edema inhibitors. European Journal of Medicinal Chemistry, 1995, 30, 915-924.	5.5	19
38	RAT INTERLEUKIN-2 IMMUNOGLOBULIN M FUSION PROTEINS ARE CYTOTOXIC IN VITRO FOR CELLS EXPRESSING THE IL-2 RECEPTOR AND CAN ABOLISH CELL-MEDIATED IMMUNITY IN VIVO. Transplantation, 1994, 58, 932-939.	1.0	8
39	The Temporal Association Between Î³Î´ T Cells and the Natural History of Insulin-Dependent Diabetes. Journal of Autoimmunity, 1993, 6, 107-119.	6.5	21
40	Increased T lymphocytes bearing the gamma-delta T cell receptor in subjects at high risk for insulin dependent diabetes. Journal of Autoimmunity, 1991, 4, 925-933.	6.5	20
41	CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects. Diabetes, 1991, 40, 1314-1318.	0.6	2
42	The Genetics of Insulin-Dependent Diabetes in the BB Rat. Current Topics in Microbiology and Immunology, 1990, 156, 87-102.	1.1	5
43	The gene for the t lymphocyte alloantigen, rt6, is not linked to either diabetes or lymphopenia and is not defective in the bb rat. European Journal of Immunology, 1989, 19, 1785-1789.	2.9	15
44	Inhibition of insulin release in vitro mediated by mononuclear cells from diabetic patients treated with cyclosporin A or placebo. Diabetes, 1988, 37, 873-877.	0.6	9
45	Cytoadherence of lymphocytes from type I diabetic subjects to insulin-secreting cells. Marker of anti-beta-cell cellular immunity. Diabetes, 1987, 36, 1356-1364.	0.6	9
46	Cyclosporin enhances diabetes induced by low-dose streptozotocin treatment in mice. Immunology Letters, 1985, 10, 57-60.	2.5	17